Star Health Q2 FY27 Results: Profit, Revenue and NCD Update

Star Health and Allied Insurance Company has reported its financial update for the quarter ended September 30, 2026, alongside details of its planned investor communication. The health insurer said Q2 FY27 profit after tax rose year-on-year, while insurance revenue also increased. The company reported profit after tax of ₹264.81 crore, compared with ₹79.58 crore in the corresponding quarter of the previous year. Insurance revenue for the quarter stood at ₹5,073.77 crore. The update also recorded the full redemption of ₹400 crore of non-convertible debentures, or NCDs. These disclosures place profitability, revenue growth and capital management at the centre of investor attention. Star Health's board was scheduled to consider unaudited Q2 and first-half FY27 results on October 27, 2026. The company has scheduled its Q2 and H1 FY27 earnings call for October 28, 2026.

Q2 profit rises from the year-earlier period

Star Health reported Q2 FY27 profit after tax of ₹264.81 crore. This compares with profit after tax of ₹79.58 crore in Q2 of the prior financial year. The year-on-year increase amounts to ₹185.23 crore based on the reported figures. The comparison indicates a substantially stronger bottom-line outcome than the corresponding quarter last year. The available interim update does not provide a detailed break-up of expenses, claims or investment income behind the quarterly change. It also does not provide a quarter-on-quarter comparison. Investors will therefore look to the detailed unaudited financial statements and management commentary for further clarity. The October 28 earnings call is the scheduled forum for management's discussion of the quarter. Until then, the reported profit and insurance revenue are the key disclosed Q2 operating indicators.

Insurance revenue reaches ₹5,073.77 crore

Insurance revenue in Q2 FY27 stood at ₹5,073.77 crore, according to the interim report. Revenue is an important measure for a health insurer because it reflects the scale of insurance business recognised during the reporting period. The reported figure is presented separately from the company's profit after tax. The source material does not state the corresponding Q2 FY26 insurance revenue figure, so a precise year-on-year revenue growth calculation cannot be made from the available data. Nor does it provide a detailed split between retail and other lines of business for the quarter. The Q2 disclosure nevertheless shows that Star Health entered the second quarter with revenue above ₹5,000 crore. The company is a standalone health insurer, making claims costs and underwriting discipline relevant factors in assessing earnings. More operating details may emerge when the full quarterly and half-year results are discussed.

₹400 crore NCD redemption completed

The company stated that ₹400 crore of NCDs were fully redeemed. NCDs are debt instruments issued by companies to raise funds. Their redemption means the stated debt obligation has been repaid in full. This is a capital-management development separate from quarterly operating profit. The disclosure does not specify the original issue date, coupon rate or maturity profile of the redeemed instruments. It also does not quantify the impact of the redemption on finance costs. However, the reported completion establishes that the ₹400 crore NCD obligation referenced in the update is no longer outstanding. Investors may seek additional details on the balance-sheet effect during the earnings call. The company also reported a solvency ratio of 2.05 in the interim update.

Solvency remains a key insurance metric

Star Health's reported solvency ratio was 2.05. For insurers, solvency is a measure of available capital relative to regulatory capital requirements. It is closely watched because insurers must maintain sufficient financial capacity to meet policyholder obligations. The reported ratio is part of the company's Q2 financial update. The available material does not provide a prior-period solvency ratio, so the direction of change cannot be determined from the supplied information. It also does not state the factors that contributed to the reported level. Still, the ratio is relevant alongside the NCD redemption because both are connected with capital and financial strength. Management commentary may provide more context on capital deployment and solvency after the half-year results. No further conclusion on regulatory capital trends can be drawn from the disclosed information alone.

Q1 performance set the recent context

The company's first-quarter FY27 disclosures provided important context for the first half. Star Health reported a 25% increase in Q1 net profit to ₹550 crore in one earnings summary. Total income was reported at ₹4,471 crore, compared with ₹3,990 crore a year earlier. Gross written premium, or GWP, increased 19% to ₹4,287 crore during that quarter. The insurer also reported underwriting profit of ₹111 crore. It settled 9.6 lakh claims and reported a 91% retail settlement ratio. Separately, a July 30 company release said normalised profit after tax was ₹386 crore in Q1 FY27, up 44% year-on-year. These are different reported profit measures, and investors should rely on the company's detailed financial statements for definitions and reconciliation.

First-half results are due for board consideration

Star Health informed the exchange that its board would meet on October 27, 2026. The agenda was to consider unaudited financial results for the quarter and half year ended September 30, 2026. The scheduled board meeting covers both Q2 FY27 and H1 FY27 performance. Half-year figures will provide a broader view than the quarterly interim update alone. In particular, investors may track revenue, premium growth, underwriting outcome, claims experience and profitability. The source material does not provide a complete H1 financial statement. It therefore does not support a calculation of first-half profit, first-half premium or margins. Any assessment of first-half performance should await the detailed results approved by the board. The company had announced the earnings-call schedule separately under Regulation 30 of the Listing Obligations and Disclosure Requirements regulations.

Earnings call scheduled for October 28

The Q2 and H1 FY27 earnings call is scheduled for October 28, 2026. This follows the board meeting planned for October 27. Such calls generally give investors and analysts an opportunity to hear management's comments on reported numbers and business conditions. The available announcement confirms the date of the call but does not provide detailed management guidance. It also does not include a transcript, presentation or questions from analysts. The call will be relevant for understanding the relationship between Q2 insurance revenue, profitability and the company's broader operating performance. It may also provide context on the NCD redemption and the reported solvency ratio. Investors will be able to compare management's discussion with the detailed unaudited results. No outcome from the call should be assumed before it is held.

Key reported figures

Why the update matters for investors

The Q2 update combines three areas that matter for an insurer: earnings, revenue and capital management. The rise in reported profit after tax from the year-earlier period is the clearest quarterly comparison available in the interim report. Insurance revenue of ₹5,073.77 crore shows the scale of business recorded during the quarter. The NCD redemption adds a balance-sheet item to the operating update. Meanwhile, the solvency ratio of 2.05 remains relevant for evaluating the insurer's financial position. Q1 data had also pointed to higher premium volumes, underwriting profit and claims settlements. However, the available material does not provide complete Q2 claims data, combined ratio, expense details or a full half-year financial statement. These disclosures will be important for a fuller assessment of the company's FY27 performance.

What to watch after the results update

The immediate next event is the Q2 and H1 FY27 earnings call on October 28, 2026. Investors will watch for the detailed unaudited results approved by the board and any explanations of the quarterly profit movement. Claims trends, underwriting performance, premium growth and expenses are likely to be relevant operating items. The company may also offer further information on the completed ₹400 crore NCD redemption. Its reported solvency ratio will remain an important capital indicator. The Q2 interim report has established the headline figures of ₹264.81 crore profit after tax and ₹5,073.77 crore insurance revenue. The full half-year disclosures will provide the broader financial context for these numbers. For now, the update points to year-on-year profit growth alongside a significant revenue base and a completed debt redemption.